A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety/tolerability of 4 doses of Imeglimin versus
placebo. The study will be performed in subjects with type 2 diabetes either naive of
treatment or previously treated with an oral monotherapy excluding thiazolidinedione.